Elisabetta Bonzano: What Drives Hormone Therapy Resistance in HR+/HER2- Breast Cancer?
Elisabetta Bonzano, Medical Director and Radiation Oncologist at IRCCS San Matteo Polyclinic Foundation, shared a post on X about a paper by Rohan Chaubal et al. published in Breast Cancer Research and Treatment:
“Genomic landscape of hormone therapy‑resistant HR‑positive, HER2‑negative breast cancer.
What drives hormone therapy resistance in HR+/HER2- breast cancer?
A new study dives deep into genomics, clonal evolution, and the role of ctDNA in predicting relapse.
- Hormone therapy – resistant HR+/HER2- tumors were polyclonal at diagnosis
- Clonal evolution with ESR1 and other driver mutations emerging at relapse
- ctDNA mirrored resistance mutations – and flagged risk in patients in ‘remission’
- Liquid biopsy holds promise for both treatment guidance and early relapse prediction.”
Title: Genomic landscape of hormone therapy-resistant HR-positive, HER2-negative breast cancer
Authors: Rohan Chaubal, Elizabeth Talker, Jaya Chitra, Rasika Kadam, Nilesh Gardi, Riddhi Ursekar, Anushree Kadam, Ankita Singh, Suhani Sale, Shwetali Pandey, Mrudula Madhav, Aishwarya Raja, Rushikesh Mukhare, Pallavi Parab, Nitin Shetty, Kunal Gala, Suyash Kulkarni, Khushboo A. Gandhi, Seema Gulia, Shalaka Joshi, Tanuja Shet, Sudeep Gupta
You can read the Full Article in Breast Cancer Research and Treatment.
More posts featuring Elisabetta Bonzano.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023